Valeda™ PBM
Finally, a treatment for dry AMD that can improve your vision.
Valeda™ PBM is the first FDA-authorized treatment for dry age-related macular degeneration that uses gentle light therapy — no needles, no dilation, no downtime.
Why patients choose it
Proven results. Total comfort.
Valeda™ PBM was designed to fit into your life — not disrupt it.
01. No needles — ever
Unlike anti-VEGF injections used for wet AMD, Valeda™ PBM involves no injections into the eye whatsoever. Just comfortable light therapy delivered through a device positioned near your eye.
Unlike anti-VEGF injections used for wet AMD, Valeda™ PBM involves no injections into the eye whatsoever. Just comfortable light therapy delivered through a device positioned near your eye.
02. Drive yourself home
No dilation drops means no blurry vision after treatment. Your eyes are ready to go the moment you leave the office — so you can drive, work, and go about your normal day without interruption.
No dilation drops means no blurry vision after treatment. Your eyes are ready to go the moment you leave the office — so you can drive, work, and go about your normal day without interruption.
03. Done in your doctor’s office
No hospital, no surgery center. Valeda™ PBM is an in-office treatment — you simply sit comfortably in front of the device while it works. Most sessions take just a few minutes per eye.
No hospital, no surgery center. Valeda™ PBM is an in-office treatment — you simply sit comfortably in front of the device while it works. Most sessions take just a few minutes per eye.
04. Proven safe across 3 studies
More than 97% of patients reported no eye pain. No phototoxicity (light damage) or serious treatment-related side effects have ever been reported across the three LIGHTSITE clinical trials.
More than 97% of patients reported no eye pain. No phototoxicity (light damage) or serious treatment-related side effects have ever been reported across the three LIGHTSITE clinical trials.
Important information: Valeda™ PBM is FDA-authorized for adults aged 50+ with dry AMD defined by the presence of at least 3 medium drusen (>63 μm and ≤125 μm in diameter), or large drusen (>125 μm in diameter), or non-central geographic atrophy. Individual results may vary. This page is for informational purposes only and does not constitute medical advice. Please consult your eye care provider to determine if this treatment is appropriate for you.